Showing results (421-430 of 494) with videos related to

Sort By:
Pageof 50
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Annals of Surgery|June 16, 2025
Global Variations in Patterns of Care for Retroperitoneal SarcomaHayden Snow, Marco Fiore, Jing Xie, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
The Lancet. Oncology|September 17, 2020
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trialSylvie Bonvalot, Alessandro Gronchi, Cécile Le Péchoux, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
Pageof 50